CLINICAL TRIALS PROFILE FOR ATRALIN
✉ Email this page to a colleague
All Clinical Trials for ATRALIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00603772 ↗ | Clinical Evaluation of the Photoallergy Potential of Atralin Gel | Completed | Coria Laboratories, Ltd. | Phase 1 | 2008-01-01 | To assess the potential of tretinoin gel 0.05% and its vehicle to produce photoallergic reactions, measured as skin reactions following induction and challenge. |
| NCT00604032 ↗ | Study to Determine the Phototoxity of Atralin (Tretinoin) Gel, 0.05% | Completed | Coria Laboratories, Ltd. | Phase 1 | 2008-01-01 | To assess the potential of tretnoin gel 0.05% to produce phototoxic reactions, measured as skin reactions 24 and 48 hours after UV radiation of drug on skin. |
| NCT00621218 ↗ | A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea | Completed | Coria Laboratories, Ltd. | Phase 2 | 2008-02-01 | To compare the efficacy and safety of tretinoin gel 0.05% to its vehicle when dosed once or twice daily in female subjects with rosacea. |
| NCT01125930 ↗ | Atralin Gel for the Treatment of Rosacea | Terminated | Bausch Health Americas, Inc. | Phase 3 | 2010-05-01 | Erythematotelangiectatic rosacea is a type of rosacea that causes a red face often with frequent flushing, topical sensitivity and prominent blood vessels. We think that long term damage to skin from the sun (photodamage) may play a role in causing this type of rosacea. Tretinoin is a topical medication that is known to improve photodamage. We want to find out if Atralin (tretinoin 0.05%) Gel used for up to 46 weeks will improve erythematotelangiectatic rosacea (ETR). |
| NCT01125930 ↗ | Atralin Gel for the Treatment of Rosacea | Terminated | Valeant Pharmaceuticals International, Inc. | Phase 3 | 2010-05-01 | Erythematotelangiectatic rosacea is a type of rosacea that causes a red face often with frequent flushing, topical sensitivity and prominent blood vessels. We think that long term damage to skin from the sun (photodamage) may play a role in causing this type of rosacea. Tretinoin is a topical medication that is known to improve photodamage. We want to find out if Atralin (tretinoin 0.05%) Gel used for up to 46 weeks will improve erythematotelangiectatic rosacea (ETR). |
| NCT01125930 ↗ | Atralin Gel for the Treatment of Rosacea | Terminated | Lisa E. Maier | Phase 3 | 2010-05-01 | Erythematotelangiectatic rosacea is a type of rosacea that causes a red face often with frequent flushing, topical sensitivity and prominent blood vessels. We think that long term damage to skin from the sun (photodamage) may play a role in causing this type of rosacea. Tretinoin is a topical medication that is known to improve photodamage. We want to find out if Atralin (tretinoin 0.05%) Gel used for up to 46 weeks will improve erythematotelangiectatic rosacea (ETR). |
| NCT01283464 ↗ | Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles | Completed | Johns Hopkins University | Phase 2 | 2010-11-01 | The purpose of this study is to assess the comparative efficacy of retinol 1.0% and tretinoin 0.02% in minimizing wrinkles, discoloration, roughness, and other signs of moderate to severe photodamage. Our hypothesis is that both products will be of comparable benefit. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ATRALIN
Condition Name
Clinical Trial Locations for ATRALIN
Trials by Country
Clinical Trial Progress for ATRALIN
Clinical Trial Phase
Clinical Trial Sponsors for ATRALIN
Sponsor Name
